secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001323885-22-000097
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q2 2022 revenue $84.5M (+18.4%); net loss $0.32/share; FY guidance unchanged
--------------------------------------------------------------------------------

- Revenue $84.5M (+18.4% YoY; +19.8% constant currency); U.S. $71.3M (+18.6%), international $13.3M (+17.3%).
- Gross margin 75.1% vs 75.8% prior; operating loss $13.7M vs $15.1M prior.
- Net loss per share $0.32 (adjusted $0.32) vs $0.36 GAAP and $0.30 adjusted prior year.
- Adjusted EBITDA loss $3.2M vs $2.7M prior; FY 2022 revenue guide $323M-$333M (18-21% growth).
- Growth driven by cryoSPHERE, AtriClip, ENCOMPASS, and EPi-Sense products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000097/0001323885-22-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000097/atrc-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001323885-22-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer